相关实验视频

Updated: Sep 14, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

在接受神经母细胞瘤治疗的儿童中,比较质子和光子治疗计划

Anna Embring¹, Ingrid Kristensen², Martin P Nilsson³

¹Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. anna.embring@ki.se.

Acta oncologica (Stockholm, Sweden)

|July 23, 2025

概括

与光子疗法相比,质子疗法显著降低了与神经母细胞瘤儿童有风险的器官的辐射剂量. 需要进一步的研究来确认这是否会导致更好的临床结果.

科学领域:

儿科瘤学儿科瘤学
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

神经母细胞瘤是最常见的儿科脑外固体瘤.
放射治疗是治疗高危神经母细胞瘤患者的关键组成部分.
了解辐射剂量分布对于最小化治疗毒性至关重要.

研究的目的:

为了比较儿童神经母细胞瘤的质子和光子疗法计划之间的危险器官辐射剂量 (OAR).
分析和报告接受神经母细胞瘤放射治疗的儿童治疗相关的副作用.

主要方法:

对30名为腹部神经母细胞瘤治疗的儿童进行了回顾性分析,使用比较的质子和光子图.
通过瑞典国家登记处 (RADTOX) 识别患者.
剂量与OAR的比较以及急性和晚期副作用的评估.

主要成果:

与光子疗法相比,质子疗法显著降低低剂量辐射传播 (体V5Gy,V10Gy) (p < 0.001).
肠囊,脏,肝脏,胰腺和脏的平均剂量在质子计划中显著下降.
在40%的患者中观察到急性副作用 (等级≥2),在13%的患者中观察到晚期副作用,血液学和上部肠道问题是最常见的.

结论:

质子疗法在儿科神经母细胞瘤治疗中提供了降低的OAR剂量和更少的低剂量暴露.
质子疗法的临床益处需要在前性研究中进一步调查.

更多相关视频

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...